FDA nod for breath-actuated QVAR inhaler

The US Food and Drug Administration (FDA) has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy.

This product, expected to become commercially available in both 40mcg and 80mcg strengths to patients by prescription during the first quarter of 2018, is from Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA). It administers the same active drug ingredient found in QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol, with a different mode of delivery.

QVAR RediHaler, which is not indicated for the relief of acute bronchospasm, differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated MDI, eliminating the need for hand-breath coordination during inhalation.